Here are the 10-Q quarterly reports from AptarGroup, Inc. (ATR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATR filings page.
AptarGroup, Inc. reported third-quarter 2026 net sales of $1.02 billion, up 6% from $961.1 million a year earlier. Core sales, excluding acquisitions, deconsolidation and changes in foreign currency rates, increased 5%. Beauty and Closures core sales grew 8% and 11%, respectively; Pharma core sales grew 1%, as growth in consumer healthcare and injectables offset lower emergency-medicine sales.
Net income attributable to AptarGroup was $32.6 million, compared with $127.9 million in the third quarter of 2025; operating income was $135.0 million versus $136.9 million. After concluding it had lost control of its Russian subsidiary, AptarGroup deconsolidated it effective September 21, 2026, recording a $58.0 million loss. The company also reported $30.0 million of subsidiary cash it could no longer access; Russian operations are no longer included in consolidated sales, earnings or net assets.
Operating cash flow was $389.8 million for the first nine months of 2026, compared with $386.3 million a year earlier. AptarGroup repurchased approximately 1.3 million shares for $180.0 million over that period, with $420.0 million remaining under the $600.0 million authorization as of September 30, 2026. The third-quarter dividend per common share was $0.48, compared with $0.45 a year earlier.
AptarGroup, Inc. reported first-quarter 2026 net sales of $982.9 million, up 11% from $887.3 million a year earlier. Foreign exchange and acquisitions drove most of the increase, leaving core sales roughly flat. Net income attributable to AptarGroup was $72.7 million, down from $78.8 million, and diluted EPS declined to $1.12 from $1.17 as margins compressed.
Pharma sales rose to $438.6 million but core sales dipped 1% on lower emergency medicine volumes, while Beauty and Closures delivered modest core growth. Operating margin decreased to 10.9% from 12.8%. Cash flow from operations strengthened to $118.7 million, supporting $65.4 million of capital spending and $100.0 million of share repurchases under a new $600 million authorization.
AptarGroup (ATR) reported higher Q3 2025 revenue and earnings. Net sales rose to $961.1 million from $909.3 million, led by Aptar Pharma ($445.4 million), Beauty ($327.8 million) and Closures ($188.0 million). Operating income was $136.9 million versus $138.3 million a year ago. Other income benefited from a $26.5 million gain from remeasurement of an equity method investment.
Profitability improved year over year. Net income attributable to AptarGroup was $127.9 million (diluted EPS $1.92) versus $100.0 million ($1.48). For nine months, sales reached $2.81 billion with net income of $318.4 million (EPS $4.75) versus $2.73 billion and $273.6 million (EPS $4.05).
Balance sheet and cash flow remained solid. Cash and equivalents were $257.1 million; total assets were $5.10 billion. Net cash provided by operations was $386.3 million. The company used cash for capital expenditures ($183.6 million), treasury stock purchases ($190.0 million) and dividends ($89.3 million). Revolving credit borrowings totaled $187.0 million and €130.0 million under the amended facility. Leverage and coverage remained well within covenants at 1.22x and 17.02x, respectively. Shares outstanding were 65,619,154 as of October 27, 2025.